Tenosynovial Giant Cell Tumors (TSGCTs) Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-32) – DelveInsight | Key Companies – Elixiron, Daiichi Sankyo, AmMax Bio, Deciphera

March 01
23:08 2023
Tenosynovial Giant Cell Tumors (TSGCTs) Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-32) -  DelveInsight | Key Companies - Elixiron, Daiichi Sankyo, AmMax Bio, Deciphera
Delveinsight Business Research LLP
As per DelveInsight, the Tenosynovial Giant Cell Tumors (TSGCTs) therapeutics market is anticipated to grow in the coming years owing to the increasing incident population of TSGCTs and the launch of the emerging drug in the 7MM.

Companies across the globe are diligently working toward developing novel treatment therapies with a considerable amount of success over the years. Key players, such as AmMax Bio, Inc., Deciphera Pharmaceuticals LLC, and others, are actively working in the TSGCTs market. Emerging novel therapies like AMB-05X, Vimseltinib, and others are awaiting approval. These emerging therapies are in the mid and late phases of clinical trials, holding significant promise and potential to manage the disease burden.

DelveInsight’s “Tenosynovial Giant Cell Tumors (TSGCTs) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Tenosynovial Giant Cell Tumors market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Tenosynovial Giant Cell Tumors market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Tenosynovial Giant Cell Tumors Market

Tenosynovial Giant Cell Tumors (TSGCTs): An Overview

Tenosynovial giant cell tumors (TSGCTs) are rare, locally aggressive, typically benign neoplasms of joints, bursae, and tendon sheaths. TSGCTs can be roughly divided into localized and diffused types. Giant cell tumor of tendon sheath is the most common form of TSGCT.

They are caused by translocating certain parts of chromosomes 1 and 2, causing the cells to overproduce a protein called colony-stimulating factor-1 or CSF-1. There are no environmental, genetic, occupational, lifestyle, demographic, or regional risk factors that have been conclusively shown to be involved with the development of these tumors. TSGCTs have a wide clinical spectrum that affects patients of all ages. The signs and symptoms of TSGCTs can vary depending on the exact location involved and the subtype present.

Tenosynovial Giant Cell Tumors (TSGCTs) Market Key Facts

  • According to DelveInsight, the total incident population of TSGCTs in the 7MM was estimated to be 33,577 cases in 2021, which is anticipated to increase in the forecasted period.

  • In Japan, the incident cases of Tenosynovial Giant Cell Tumors (TSGCTs) were found to be 4,833 cases for (TSGCTs) in 2021; this accounts for 14% of the total incident cases of TSGCTs in the 7MM.

  • The incident cases of TSGCTs in EU4 and the UK were 14,443 in 2021, these cases will increase by 2032. Among the European countries in our scope, Germany has the highest incident population with 3,759 cases followed by France and the UK with 2,909 cases. The lowest incident cases were observed in Spain with 2,102 cases in 2021.

  • The total incident population of TSGCTs in EU4 and the UK was 43% of the total incident population among the 7MM in 2021.

Tenosynovial Giant Cell Tumors (TSGCTs) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Tenosynovial Giant Cell Tumors market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Tenosynovial Giant Cell Tumors market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Tenosynovial Giant Cell Tumors Epidemiology, Segmented as –

  • Incident cases of Tenosynovial Giant Cell Tumor (TSGCTs) in the 7MM (2019–2032)

  • Gender-specific Incident cases of Tenosynovial Giant Cell Tumor (Land D-TSGCTs) in the 7MM (2019-2032)

  • Growth Pattern-specific Incident cases of Tenosynovial Giant Cell Tumor (TSGCTs) in the 7MM (2019–2032)

  • Tumor Localization of Tenosynovial Giant Cell Tumor (L and D-TSGCTs) in the 7MM (2019-2032)

Tenosynovial Giant Cell Tumors (TSGCTs) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Tenosynovial Giant Cell Tumors market or expected to be launched during the study period. The analysis covers the Tenosynovial Giant Cell Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Tenosynovial Giant Cell Tumors pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Tenosynovial Giant Cell Tumors Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market

Tenosynovial Giant Cell Tumors (TSGCTs) Therapeutics Analysis

Several major pharma and biotech giants are developing therapies for Tenosynovial Giant Cell Tumors. Currently, Deciphera Pharmaceutical is leading the therapeutics market with its Tenosynovial Giant Cell Tumors drug candidates in the most advanced stage of clinical development.

Key Companies in the Tenosynovial Giant Cell Tumors (TSGCTs) Therapeutics Market Include:

  • Abbisko Therapeutics Co, Ltd.

  • AmMax Bio, Inc.

  • Daiichi Sankyo

  • Deciphera Pharmaceuticals

  • Elixiron Immunotherapeutics

  • Hutchison Medipharma Limited

  • SynOx Therapeutics

And Many More

Tenosynovial Giant Cell Tumors (TSGCTs) Emerging and Marketed Drugs Covered in the Report Include:

  • Vimseltinib: Deciphera Pharmaceuticals

  • EI-1071: Elixiron Immunotherapeutics

  • TURALIO (pexidartinib): Daiichi Sankyo

  • AMB-05X: AmMax Bio, Inc.

And Many More 

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Tenosynovial Giant Cell Tumors Competitive Intelligence Analysis

4. Tenosynovial Giant Cell Tumors Market Overview at a Glance

5. Tenosynovial Giant Cell Tumors Disease Background and Overview

6. Tenosynovial Giant Cell Tumors Patient Journey

7. Tenosynovial Giant Cell Tumors Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Tenosynovial Giant Cell Tumors Treatment Algorithm, Current Treatment, and Medical Practices

9. Tenosynovial Giant Cell Tumors Unmet Needs

10. Key Endpoints of Tenosynovial Giant Cell Tumors Treatment

11. Tenosynovial Giant Cell Tumors Marketed Products

12. Tenosynovial Giant Cell Tumors Emerging Drugs and Latest Therapeutic Advances

13. Tenosynovial Giant Cell Tumors Seven Major Market Analysis

14. Attribute Analysis

15. Tenosynovial Giant Cell Tumors Market Outlook (In US, EU5, and Japan)

16. Tenosynovial Giant Cell Tumors Access and Reimbursement Overview

17. KOL Views on the Tenosynovial Giant Cell Tumors Market

18. Tenosynovial Giant Cell Tumors Market Drivers

19. Tenosynovial Giant Cell Tumors Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-market 

 

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories